Abstract
The evolution of opinion as to how to analyse the AB/BA cross-over trials is described by examining the recommendations of three key papers. The impact of these papers on the medical literature is analysed by looking at citation rates as a function of various factors. It is concluded that amongst practitioners there is a highly imperfect appreciation of the issues raised by the possibility of carryover.
Original language | English |
---|---|
Pages (from-to) | 123-131 |
Number of pages | 9 |
Journal | Pharmaceutical Statistics |
Volume | 3 |
Issue number | 2 |
DOIs | |
Publication status | Published - Apr 2004 |
Externally published | Yes |
Keywords
- Carry-over
- Citation analysis
- Generalized linear model